Pfizer Inc. stock steady as Guggenheim hikes target to $36 amid Lyme vaccine Phase 3 success

Pfizer Inc. stock remained steady on the NYSE at around $26.77 USD following key analyst upgrades and promising Phase 3 data from its Lyme disease vaccine candidate. Guggenheim lifted its price target to $36 from $35 while keeping a buy rating, reflecting confidence in the company's operational momentum as of March 24, 2026. This comes alongside Jefferies reaffirming its buy recommendation with a $34 target, drawing attention to Pfizer's potential in underserved vaccine markets.

As of: 26.03.2026

Dr. Elena Marquez, Senior Pharma Equity Analyst: Pfizer's Lyme vaccine progress highlights resilient R&D execution, offering US investors a defensive growth play amid patent expirations and sector rotation.

Analyst Upgrades Signal Confidence in Pfizer's Trajectory

Guggenheim's adjustment to a $36 price target underscores belief in Pfizer's ability to navigate post-COVID challenges while advancing its pipeline. The firm maintained its buy rating, citing operational improvements and upcoming catalysts. Jefferies analyst Akash Tewari echoed this sentiment, upholding a buy stance with a $34 target in a recent note.

These updates contrast with the broader consensus. Out of 28 analysts, the average target stands at $28.54, suggesting about 6.62% upside from the recent NYSE close of $26.77 USD. Pfizer Inc. stock was last seen on NYSE at $26.77 USD, down 0.74% in the prior session, with pre-market trades hovering near $26.80 USD.

Such target hikes are particularly relevant in pharma, where valuations hinge on pipeline milestones, cost controls, and revenue diversification. For Pfizer, these signal undervaluation relative to peers, especially as the company balances legacy blockbusters with new launches.

Lyme Vaccine Phase 3 Data Revives Pipeline Momentum

Pfizer and partner Valneva reported on March 23, 2026, that their Lyme disease vaccine candidate, LB6V, achieved over 73% efficacy in preventing infections in the Phase 3 Valor trial. The vaccine demonstrated strong primary endpoint results, positioning it as a potential first-in-class preventive option despite missing a secondary goal.

Safety profiles were favorable, with no major concerns noted. Lyme disease affects an estimated 476,000 people annually in the US, primarily in the Northeast and Midwest, creating a substantial domestic market opportunity. This data marks a win for Pfizer's vaccines business, which has faced scrutiny post-COVID revenue peaks.

US investors stand to benefit from accelerated FDA pathways for endemic diseases. Reimbursement tailwinds in high-prevalence regions could drive uptake, diversifying Pfizer's infectious disease portfolio beyond antivirals.

Why US Investors Should Watch Pfizer Now

With 60.8% of net sales from the United States, Pfizer remains a cornerstone for US portfolios seeking pharma exposure. Primary care (47.4%), specialty care (26.2%), and oncology (24.5%) segments anchor revenues, supported by mRNA platforms and antivirals.

The Lyme vaccine taps directly into US public health needs, potentially speeding approvals and adoption. Pfizer's ESG MSCI A rating appeals to sustainable investing trends, while its dividend aristocrat status offers yield stability amid biotech volatility.

For US investors, these developments highlight Pfizer's shift from COVID dependency toward a balanced portfolio. Analyst buy ratings suggest room for multiple expansion if execution continues.

Broader Pharma Sector Context and Valuation

Pfizer trades at a forward P/E of around 17.9x, below sector averages, with a PEG ratio near 0.01 indicating growth potential. Price-to-book stands at 1.6x, reflecting solid asset backing.

Consensus implies modest upside, but selective buy calls from Guggenheim and Jefferies point to optimism. Healthcare's defensive posture amid market rotations favors established players like Pfizer with pipeline catalysts.

NYSE liquidity supports institutional interest, with recent stability post-news showing measured market digestion.

Risks and Open Questions Ahead

While primary efficacy is strong, the missed secondary endpoint raises questions on full profile durability. FDA feedback will be critical for labeling and approval timelines.

Patent cliffs loom for key products, pressuring margins unless offset by launches. Valneva's sharp share drop highlights partnership risks, though Pfizer's scale mitigates impact.

Macro factors like drug pricing reforms and reimbursement changes could cap upside. US investors must weigh pipeline promise against execution hurdles in a competitive landscape.

Strategic Implications for Pfizer's Portfolio

Lyme success bolsters Pfizer's vaccines franchise, targeting gaps left by prior failures. Combined with Comirnaty updates for 2025-2026, it signals sustained R&D investment.

Oncology and specialty care provide buffers, with mRNA tech enabling rapid adaptation. For US investors, this positions Pfizer as a hybrid defensive-growth name.

Dividend reliability and buybacks enhance total returns, appealing in uncertain markets.

Disclaimer: This is not investment advice. Stocks are volatile financial instruments.